Investigational Hepatitis C Quad Therapy Regimen of Daclatasvir and Asunaprevir Plus Interferon Alfa and Ribavirin Achieved SVR24 in 93% of Difficult-to-Treat Genotype 1a/b Prior Null Responders in Expanded Phase II Study